SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 272 filers reported holding SAGE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.97 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $6,630,000 | -50.8% | 91,847 | -4.5% | 0.28% | -42.4% |
| Q3 2019 | $13,486,000 | -26.5% | 96,129 | -4.1% | 0.50% | +1.0% |
| Q2 2019 | $18,349,000 | +34.1% | 100,220 | +16.5% | 0.49% | +40.8% |
| Q1 2019 | $13,679,000 | +40.7% | 86,003 | -15.3% | 0.35% | +26.5% |
| Q4 2018 | $9,722,000 | -25.9% | 101,490 | +9.2% | 0.28% | +5.0% |
| Q3 2018 | $13,127,000 | -10.3% | 92,931 | -0.6% | 0.26% | -13.2% |
| Q2 2018 | $14,635,000 | +221.2% | 93,496 | +230.5% | 0.30% | +228.3% |
| Q1 2018 | $4,556,000 | +30.4% | 28,285 | +33.3% | 0.09% | +39.4% |
| Q4 2017 | $3,495,000 | +222.1% | 21,222 | -41.1% | 0.07% | +500.0% |
| Q2 2016 | $1,085,000 | – | 36,005 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |